New hope for lung cancer patients who stopped responding to standard treatment
NCT ID NCT06903377
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tests a new two-drug combination (ZG005 and gecacitinib) in people with advanced non-small cell lung cancer that has not responded to standard PD-1/L1 therapy. The goal is to see if the combination is safe and can shrink tumors. About 50 adults aged 18 to 75 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.